Workflow Schematic

Optimization of T Cell RNA Delivery & Multiplex Gene Knockdown.
Primary human T cells were electroporated using the MaxCyte GTx® and transfected cells examined by flow cytometry. (A) T cells were electroporated with mRNA encoding GFP at various electroporation energies. Medium and high energy protocols produced 100% GFP+ cells with cell viabilities >70%. (B) T cells were electroporated with Cas9 mRNA and gRNA targeting CD7 alone or gRNAs targeting CD7 and TRAC. CD7 single knockdown and CD7/TRAC dual gene deletion efficiencies were 94%. Data courtesy of Washington University in St. Louis.
Summary
- Non-viral engineering enables rapid development of next-generation therapies — such as endogenous T cell receptor knockout or disruption of checkpoint inhibitors — with the benefit of simplified, more cost-effective manufacturing
- MaxCyte Flow Electroporation® Technology (co)delivers a diversity of payloads including mRNA, sgRNA, RNPs, and plasmid & minicircle DNA providing flexibility for sophisticated, non-viral engineering including:
– transient mRNA expression
– nuclease-mediated gene editing (CRISPR, TALEN, ZFN)
– transposon insertion (Sleeping Beauty, piggyBac) - MaxCyte clinical scalability and regulatory compliance provide for streamlined clinical translation of new therapies.
- The high efficiency and low toxicity of MaxCyte Flow Electroporation provides for strong expression of exogeneous genes such as CARs and/or high gene disruption frequencies that bolster therapeutic efficacy.
- Development and optimization of MaxCyte Flow Electroporation for new cell types and payloads is a rapid, straightforward process.